RecruitingNot ApplicableNCT04900935

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Sponsor

Massachusetts General Hospital

Enrollment

70 participants

Start Date

Sep 29, 2023

Study Type

INTERVENTIONAL

Conditions

Carcinoma, Non-Small Cell Lung Survivorship Targeted Therapy Nonsmall Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer EGFR Positive Non-small Cell Lung Cancer ALK-positive Non-small Cell Lung Cancer Palliative Care

Summary

The goal of this study is to develop and test the feasibility of a supportive care model (POISE) for patients with metastatic Non-small Cell Lung Cancer (NSCLC). The main questions are * is POISE feasible to deliver and acceptable to patients * what is the effect of POISE on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect Participants in the randomized controlled trial will receive either the new supportive care model, POISE, which consists of four visits with a trained palliative care clinician, or care as usual, and will be asked to complete three surveys.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests the best way to combine survivorship care and palliative (comfort-focused) care for people with advanced lung cancer that has a specific genetic mutation. It aims to improve quality of life alongside cancer treatment. **You may be eligible if...** - You are 18 or older and a patient at Massachusetts General Hospital Cancer Center - You were diagnosed with metastatic non-small cell lung cancer (NSCLC) with a driver mutation (EGFR, ALK, ROS1, or RET) within the past 6 months - You are currently receiving targeted therapy - You can communicate in English or Spanish **You may NOT be eligible if...** - You have significant cognitive impairment or serious mental illness - You need urgent palliative care or hospice immediately - You are pregnant or incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPOISE

POISE (Patient-centered, Optimal Integration of Survivorship and palliative carE) is a brief, population-specific intervention that consists of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with long, uncertain cancer trajectories.

Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04900935

Related Trials

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT0723069160 locations

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428110 locations

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT0722702515 locations

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT0611678615 locations

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076200 locations